TCGA-A8-A07G-01A-11R-A034-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 19
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- ANGIOGENESIS+0.370
- PROTEIN_SECRETION+0.360
- BILE_ACID_METABOLISM+0.320
- CHOLESTEROL_HOMEOSTASIS+0.320
- UV_RESPONSE_DN+0.300
- COAGULATION+0.290
- APICAL_JUNCTION+0.250
- KRAS_SIGNALING_UP+0.250
- MTORC1_SIGNALING+0.240
Top 10 suppressed
- MYC_TARGETS_V2-0.580
- E2F_TARGETS-0.530
- G2M_CHECKPOINT-0.470
- DNA_REPAIR-0.320
- MYC_TARGETS_V1-0.300
- TNFA_SIGNALING_VIA_NFKB-0.220
- UV_RESPONSE_UP-0.190
- SPERMATOGENESIS-0.160
- OXIDATIVE_PHOSPHORYLATION-0.140
- WNT_BETA_CATENIN_SIGNALING-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-FD-A3SM-01A-11R-A22U-07 | — | — | 0.827 |
| 2 | SRR8518203 | — | A | 0.788 |
| 3 | TCGA-CR-7401-01A-11R-2016-07 | — | — | 0.786 |
| 4 | SRR8518353 | — | F | 0.782 |
| 5 | 27a08af2-4626-4bf9-bdf6-a6ba644a53a2 | — | — | 0.781 |
| 6 | 20060030.TNBC | — | F | 0.779 |
| 7 | TCGA-38-4627-01A-01R-1206-07 | — | cohortA1 | 0.776 |
| 8 | TCGA-D8-A1XU-01A-11R-A14M-07 | — | A | 0.773 |
| 9 | SRR8518340 | — | F | 0.771 |
| 10 | TCGA-AO-A0JF-01A-11R-A056-07 | — | A | 0.768 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.360 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| HYPOXIA | 0.180 | Idelalisib | — uncovered |
| MYOGENESIS | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |